{"publication_id":"fa3d00ab-72a0-4cb6-aaa0-48b50e0f9875","screening":{"identified":13,"screened":13,"excluded":0,"included":13,"included_or_retained":13,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"13 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["The conclusion is that oral microbiome periodontal aging should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","The curated corpus is composed entirely of observational cohort designs, with no randomized controlled trials or quasi-experimental studies of oral microbiome interventions and aging-related outcomes represented. While mechanistic and associative signals are plentiful, the absence of interventional evidence means that causal claims about microbiome-directed therapies for periodontitis or age-related oral dysbiosis cannot be drawn from this body of work. Long-term mortality or hard cardiovascular endpoint trials involving the oral microbiome–periodontal disease axis were not identified in the corpus, creating a fundamental gap between microbiome signatures and clinically actionable endpoints. As such, conclusions about the therapeutic potential of modulating the oral microbiome for aging-related periodontitis remain provisional and hypothesis-generating only.","Several outcome domains within this synthesis rest on single-study evidence, precluding within-corpus replication or triangulation. For example, the association between oral microbiome composition and cognitive performance is supported solely by Adnan 2025, while the link between periodontal dysbiosis and non-alcoholic fatty liver disease rests exclusively on Kuraji 2024, an animal-model study using a nisin lantibiotic intervention in mice. Similarly, the koala-specific microbiome–periodontal disease data from Pettett 2025 represents a unique taxonomic context that cannot be cross-validated against any other source in the corpus. These single-trial touchpoints mean that effect sizes and directionality for these associations remain unconfirmed and may not generalize beyond their original study populations.","The endpoint scope of the corpus is predominantly compositional and inflammatory rather than functional or clinically hard. Most studies reported microbial diversity metrics, taxonomic shifts, and salivary or serum cytokine levels (Gottschalk 2026, Plachokova 2021, Ishihara 2025), but none captured tooth loss, edentulism incidence, or validated periodontal treatment success rates as primary aging-relevant endpoints. Furthermore, the mechanism-to-clinic gap is pronounced: Viana 2025 provides a mechanistic narrative linking neutrophil lifespan and oral microbiome dysbiosis, yet no source in the corpus bridges this mechanistic pathway to a measured clinical outcome in older adults, leaving the translational logic from immune cell biology to periodontal aging outcomes empirically unsupported.","For oral microbiome periodontal aging, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","Across 13 curated reference papers, the evidence base for Oral microbiome shows a context-dependent profile. Null findings dominate: contextual other, immune inflammation. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Oral microbiome anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."]}